36822-09-0Relevant academic research and scientific papers
Synthesis method of iridium-containing complex
-
, (2020/08/02)
The invention discloses a synthesis method of an iridium-containing complex. The synthesis method is characterized in that a compound Ir (La) (Lb) 2 is prepared through one-step reaction of a substance shown in the specification and La in the presence of one or more solvents or in the absence of solvents. The synthesis method is suitable for an iridium-containing complex containing two same bidentate C-N ligands and one bidentate 1, 3-diketone, 1, 3-dithione or 1, 3-diimine ligand. Compared with the traditional synthesis method, the synthesis method has higher synthesis efficiency, can be carried out under milder reaction conditions, and can realize the synthesis of some complexes which cannot be realized by the traditional method. The iridium-containing complex prepared by the synthesis method is easier to be used in production and manufacturing of organic electroluminescent devices.
Bicarbazole containing compounds for OLED
-
, (2015/02/02)
The present disclosure generally relates to novel compounds containing carbazole and triazine with different number of phenyl units attached to its core. In particular, the disclosure relates to compositions and/or devices comprising these compounds as ho
DONOR-ACCEPTOR COMPOUNDS WITH NITROGEN CONTAINING HETEROPOLYAROMATICS AS THE ELECTRON ACCEPTOR
-
, (2016/10/10)
Disclosed is a light emitting substance that is used as an emitter in an organic light emitting diode. The light emitting substance includes a donor-acceptor compound having a high triplet energy heteropoly aromatic system. In other words, the donor-acceptor compound includes dibenzofuran, dibenzothiophene, and dibenzoselenophene that are electron acceptors and have multiple nitrogen atoms in one ring. The compound is represented by Chemical Formula 1 below.COPYRIGHT KIPO 2015
Synthesis and evaluation of apoptosis induction of thienopyrimidine compounds on KRAS and BRAF mutated colorectal cancer cell lines
Pedeboscq, Stephane,Pometan, Jean-Paul,Gravier, Denis,Casadebaig, Francoise,Hou, Genevieve,Gissot, Arnaud,Rey, Christophe,Ichas, Francois,Giorgi, Francesca De,Lartigue, Lydia
, p. 6724 - 6731,8 (2012/12/12)
Monoclonal antibodies (MoAb) and tyrosine kinase inhibitors (TKI) targeting the EGFR (Epidermal Growth Factor Receptor) pathways are currently used in colorectal cancer treatment. Despite the improvement of median overall survival, resistance is observed
PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE
-
, (2012/10/18)
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain fused triaryl amine compounds of the following formula (for convenience, collectively referred to herein as "FTA compounds"), which, inter alia, inhibit LIM kinase (LIMK) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit LIMK activity, and in the treatment of diseases and conditions that are mediated by LIMK, that are ameliorated by the inhibition of LIMK activity, etc., including proliferative conditions such as cancer (e.g., breast cancer, prostate cancer, melanoma, glioma, etc.), as well as vasodilation (including, e.g., hypertension, angina, cerebral vasospasm, and ischemia following subarachnoid hemorrhage), neurodegenerative disorders, atherosclerosis, fibrosis, and inflammatory diseases (including, e.g., Crohn's disease and chronic obstructive pulmonary disease (COPD)), and glaucoma (also known as ocular hypertension).
Tyrosine kinase inhibitors. 16. 6,5,6-Tricyclic benzothieno[3,2-d]pyrimidines and pyrimido[5,4-b]- and -[4,5- b]indoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase
Showalter, H. D. Hollis,Bridges, Alexander J.,Zhou, Hairong,Sercel, Anthony D.,McMichael, Amy,Fry, David W.
, p. 5464 - 5474 (2007/10/03)
Several elaborations of the fundamental anilinopyrimidine pharmacophore have been reported as potent and selective inhibitors of the epidermal growth factor receptor (EGFr) tyrosine kinase. This paper reports on a series of inhibitors whereby some 6,5-bicyclic heteroaromatic systems were fused through their C-2 and C-3 positions to this anilinopyrimidine pharmacophore. Although the resulting tricycles did not produce the enormous potency of some of the (5/6),6,6-bicyclic systems, the best of them had IC50s for the EGFr TK around 1 nM. Investigation of 4-position side chains in the indolopyrimidines confirmed that m-bromoaniline was an optimal substituent for potency. Investigation of substitution within the C-(benzo)ring of benzothienopyrimidines confirmed that introduction of an extra ring can change sharply the effects of substituents when compared to similar bicyclic nuclei, and only two substituents were found which even moderately enhanced inhibitory activity over the parent compound for this series.
